• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Phathom Pharmaceuticals

    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers HTGC PHAT
    Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Phathom Pharmaceuticals Reports Second Quarter 2023 Results
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Tickers PHAT
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.